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Abstract: Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers.
Despite improvements in medical treatments, the prognosis for EOC remains poor, and there is
an urgent need for new therapeutic strategies. Immune checkpoint inhibitors (CPIs) have dramatically
improved survival of several cancers and are under evaluation in OC. Unfortunately, CPIs have
shown globally unsatisfactory results. The aim of this manuscript is to critically review the results
from early-phase trials with CPIs in terms of safety and activity, discuss the possible reasons for
disappointing results and the new therapeutic approaches to improve patient outcomes.
Keywords: Ovarian cancer; immunotherapy; immune checkpoint inhibitors; safety; biomarkers;
clinical trials
1. Background
Epithelial ovarian cancer (EOC) is the second most common gynecological malignancy with more
than 21,750 estimated new cases in US and over 13.900 deaths in 2020 [1].
Most patients (over 70%) are diagnosed with advanced-stage disease and have a five-year survival
rate of 29% [2,3] despite multimodal treatment including optimal debulking surgery (no residual tumor)
followed by platinum-based chemotherapy (with or without bevacizumab) being the mainstay of
initial treatment, although most patients relapse with chemoresistant disease [3–10]. Recently, several
inhibitors of the enzyme poly ADP ribose polymerase (PARPi) have been approved in EOC: Olaparib for
BRCA-mutated patients as maintenance after first-line chemotherapy and at platinum-sensitive relapse;
Niraparib and Rucaparib at platinum-sensitive relapse regardless BRCA status. A progression-free
survival (PFS) improvement was observed for all drugs but, to date, with no impact on overall survival
(OS) [11–17]
Starting from this background, there is clearly a need to develop new therapies. Substantial
evidence indicates that EOCs express a multitude of known tumor-associated and mutational antigens
(TAAs or neo-antigens, respectively), and a proportion of tumors are infiltrated by intraepithelial
tumor-infiltrating lymphocytes (TILs), which correlate with improved survival [18–20]. Furthermore,
the expression of genes and molecular patterns associated with the immune response identified by
The Cancer Genome Atlas Network are associated with longer OS [21–24].
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However, despite the success of immunotherapy in other malignancies such as in melanoma,
non-small cell lung cancer (NSCLC) and urothelial cancers [25,26], the use of antibodies inhibiting
the immune checkpoint programmed cell death (PD-1) or its ligand (PD-L1) obtained modest results in
EOC so far, with median response rates of 10% up to 15% [18–20,27].
Interestingly, the combination of the anti-PD1 nivolumab and the anti-lymphocyte-associated
protein 4 (anti-CTLA4) ipilimumab showed promising results in platinum-resistant EOC at six-month
interim analyses with an overall response rate (ORR) of 34% (doubling the results of nivolumab
monotherapy). However, final results are still awaited [28].
As a consequence, no immunotherapeutic agent has obtained regulatory approval for EOC
thus far.
2. PD1/PD-L1
Immune checkpoint regulators are important modulators of the immune system.
These molecules play a central role to control self-tolerance, autoimmunity and regulate tissue
damage induced by immune responses.
The most studied immune checkpoints inhibitors (CPIs) are those involving PD1/PD-L1 and
CTLA-4/CD80/CD86 pathways.
PD-1 is a cell surface co-inhibitory receptor member of the CD28/CTLA-4 family. Physiologically,
it is mainly expressed on lymphocytes but also in monocytes and natural killer T cells, following their
activation. After binding to its ligands, PD-1 receptor inhibits CD8+ T-cell proliferation and activation
and modulates interferon-γ (IFN-γ), tumor necrosis factor-α (TNF- α) and IL-2 production. PD-1 is
also highly expressed in regulatory T cells (Tregs), and the binding between PD-1 receptor and its
ligand increases Tregs suppressive activity [29,30].
The expression of PD-1 ligands in both tumor cells and tumor-associated macrophages is one of
the main mechanisms leading to immune evasion [31]. In this context, the inhibition of the binding
between PD-1 and CTLA-4 with its receptors may improve the cytotoxic CD8+ T-cell effectiveness
resulting in a higher antitumor activity.
3. Early-Phase Clinical Trials in EOC
A better understanding of the immune checkpoint pathways paved the way for the use of CPis in
several malignancies. Early-phase trials recruiting EOC patients have been published in the last few
years. We will discuss the main features and results below.
As for PD-L1 inhibitors, results from two phase I trials have been reported.
In the first one, atezolizumab activity and safety were assessed in patients with recurrent uterine
(15 cases) and ovarian (12 cases) cancer. In the EOC cohort, 11 patients (91.7%) experienced any grade
of treatment-related AEs; of these, two patients had grade 3 events. Nine patients were evaluable for
response with an ORR of 22.2% and a DCR of 22.2%. A PD-L1 ≥5% expression on tumor-infiltrating
immune cells expression was observed in eight patients, and two of them experienced an objective
response (OR) [32].
In the phase Ib study JAVELIN solid tumor, avelumab showed a safe profile in 125 patients with
recurrent or refractory EOC. Nine patients (7.2%) had grade 3–4 treatment-related AEs, and 21 patients
(16.8%) experienced immune related events of any grade. Data on activity showed an overall response
rate (ORR) of 9.6% with only 1 complete response (CR) and a disease control rate (DCR) of 52%. In this
study, the expression of PD-L1 did not correlate with the clinical response [33].
As for PD-1 inhibitors, pembrolizumab had a manageable safely profile in a phase Ib study
(KEYNOTE-028). This study recruited 26 patients with recurrent OC and PD-L1 expression. Nineteen
patients (73.1%) experienced any grade treatment-related AEs, above all G1 and 2, and the most
frequent were arthralgia (19.2%), nausea (15.4%) and pruritus (15.4%). Only one G3 AE (transaminase
elevation) was registered, and no deaths or discontinuations due to AEs were reported. ORR was
11.5% (3 patients) in this cohort [34].
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On the basis of these results, pembrolizumab activity was further evaluated in KEYNOTE-100,
the largest phase II trial in this setting [35]. It recruited 376 patients with recurrent OC, divided in two
cohorts: cohort A, including women that received more than one and less than three prior lines with
a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12 months; and cohort B,
including heavily pretreated patients (four to six prior lines) with a PFI or TFI longer than 3 months.
Overall, an OR was achieved in 30 patients (8%) with a DCR of 37% in the combined cohort.
Specifically, ORR was 7.4% in cohort A and 9.9% in cohort B. Median progression-free survival (PFS)
was 2.1 months in both cohorts, with a median overall survival (OS) not reached in cohort A and of
17.6 months in cohort B. The expression of PD-L1 was evaluated using a combined positive score (CPS)
that is “the fraction of PD-L1 staining cells (both tumor cells, and immune cells) over the total number
of viable tumor cells”. In patients with CPS <1, ORR was 5.0%, whereas it was 10.2% for CPS ≥1 and
17.1% for CPS ≥10 patients.
Toxicity profile was consistent with KEYNOTE-028; any grade AEs were recorded in 73.1% of
patients with 19.7% of them with grade 3–5 AEs.
Another phase II study [36] evaluated the activity and safety of nivolumab (intravenous infusion
every 2 weeks at a dose of 1 or 3 mg/kg) in 20 patients with platinum-resistant EOC. It showed a best
overall response rate (BOR) of 15% and a DCR of 45%. Median PFS was 3.5 months (95% CI, 1.7 to
3.9 months), and the median OS was 20.0 months.
Grade 3–4 treatment-related AEs occurred in 40% of cases, and two patients experienced severe AEs.
Moreover, no relationship was observed between response to nivolumab and the expression of
PD-L1, suggesting, once again, a limited role of this biomarker in assessing response to therapy.
A summary of the already published data from phase 1 and 2 studies exploring CPIs in OCs is
shown in Table 1.
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Table 1. Results from phase 1 and 2 studies exploring efficacy and safety of single-agent CPIs in recurrent OC.
Study Drug Phase Clinical Setting PrimaryEnd Point
Number of
Included
Patients
Most Common Adverse
Events Reported
(Any Grade)
ORR PFS(Months)
OS
(Months) Ref
JAVELIN solid
tumors,
NCT01772004
Avelumab
(Anti PD-L1) 1
Recurrent or
refractory disease
OC, FTC or PPC
DLTs,
BOR 125
Fatigue (14%),
diarrhea (12%),
nausea (11%)
9.6% 10.2 11.2 Disis et al[33]
NCT01375842 Atezolizumab(Anti PD-L1) 1
Recurrent or
metastatic EOC or
advanced/recurrent
uterine cancer
DLTs, MTD,
RP2D,
%AEs
12
Fatigue (33%),
chills (33%),
pain (33%),
pyrexia (33%)
22.2% 2.9 11.3 Liu et al[32]
KEYNOTE-028,
NTC02054806
Pembrolizumab
(Anti PD-1) 1b
Recurrent
advanced OC,
FTC or PPC
BOR 26 Arthralgia (19%), nausea(15%), pruritus (15%) 11.5% 1.9 13.8
Varga et al
[34]
KEYNOTE-100,
NCT02674061
Pembrolizumab
(Anti PD-1) 2
Recurrent OC,
FTC or PPC ORR 376
Fatigue (34%),
nausea (15%),
decreased appetite (11%),
hypothyroidism (11%)
8.0% 1.9 13.8 Matuloniset al [35]
UMIN00005714 Nivolumab(Anti PD-1) 2
Advanced or
relapsed,
platinum-resistant
OC
ORR, PFS,
OS 20
AST increased (40%),
hypothyroidism (40%),
lymphocytopenia (35%)
15% 3.5 20.0 Hamanishiet al [36]
BOR: best overall response, CPIs: checkpoint inhibitors, DLTs: dose-limiting toxicities, FTC: fallopian tube cancer, OC: ovarian cancer, ORR: objective response rate, OS: overall survival,
MTD: maximum tolerated dose, PPC: primary peritoneal cancer, PFS: progression-free survival, RP2D: recommended phase II dose.
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4. Adverse Events in Ovarian Cancer Trials
Of all the adverse events (AEs) related to immunotherapy, the most common are fatigue,
gastrointestinal, endocrine and dermatological events. Furthermore, although less frequently,
neurological, cardiological, pulmonary and renal toxicities are being reported. Overall, 75% of
patients treated with ipilimumab experience AEs (of any grade), while in the case of PD/PDL-1
inhibitors, AEs are reported in 30% of cases [37,38]. A recent large retrospective analysis showed an
incidence of fatal outcomes in 0.36% of patients treated with PD1 inhibitors and in 1.23% of patients
treated with combined therapy (PD1 inhibitors plus anti CTLA-4). The adverse effects with the highest
mortality rate are colitis, pneumonia and myocarditis [39,40].
The toxicity data of immunotherapy in the EOC treatment are preliminary and come only
from phase 1 and phase 2 studies with a relatively low number of recruited patients [32–36]. In
these studies, the main side effects experienced by patients are fatigue (7%–41.7%), nausea and/or
vomiting (11.5%–25%), hypothyroidism (7.710.6%) and arthralgia (16.7%–25%). Cardiotoxicity is
a rare AE during therapy with immune checkpoint inhibitors (CPIs), but surprisingly in the clinical
trial UMIN000005714 [36], 6 patients out 20 with arrhythmia, without evidence of myocarditis,
were reported.
Moreover, the KEYNOTE-100 study reported a discontinuation rate of 5.1% due to
treatment-related AEs [35]. Despite a strong preclinical rationale for the use of CPIs in EOC, the results
of these studies show an overall low response rate at the expense of a certain percentage of AEs.
Furthermore, there are currently no available data on the quality of life with these treatments in
EOC patients.
5. What Can We Do to Improve the Outcomes of Immune Checkpoint Inhibitors?
5.1. Better Patient Selection
5.1.1. Predictive Biomarkers
A crucial point in immuno-oncology, not only for EOC, is to find reliable biomarkers in order to
identify the patients who will respond to ICIs.
Several biomarkers have a higher level of validation such as PD-L1 expression on cancer cells and
microsatellite instability (MSI); others, such as BRCA mutation status and tumor mutation burden
(TMB) showed more often contradictory results [41].
5.1.2. PD-L1 Assessment
A positive correlation between a high expression of PD-L1 on tumor cells and the clinical response
to immunotherapy has been observed in several cancers, most notably LC and urothelial cancer [42].
Unfortunately, these results were not confirmed in EOC by the study of Hamanishi et al., reporting a 68%
rate of PD-L1 expression in 70 patients. Patients with a higher expression of PD-L1 were found to have
a significantly poorer prognosis compared with patients with lower expression. The five-year survival
rates for patients with high-expressing versus low-expressing PD-L1 tumors were 52.6% ± 7.7% versus
80.2% ± 8.9% (p = 0.016).
Failure to use PD-L1 as a marker of response to immune CPIs may be related to the following
reasons: the method for detecting and measuring the expression of PD-L1, the identification of
a cut-off level for positivity, the predictive value of PD-L1 based on the type of cell expression (tumor,
lymphocyte, dendritic cell, macrophage), the impact of tumor heterogeneity on the predictive value of
PD-L1 and the evaluation of the PD-L1 expression on the primary tumor versus the recurrence.
Interestingly, a better correlation was observed when the PD-L1 expression was measured as
combined positive score (CPS), defined as the number of PD-L1-positive cells (tumor cells, lymphocytes,
and macrophages) divided by the total number of viable tumor cells and multiplied by 100 [43];
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however, despite a higher ORR in patients with CPS >10, this result is comparable with single-agent
chemotherapy [44].
Moreover, PD-L1 assessment is even more complex if we consider that, currently, different
anti-PD-L1 antibody clones with differences in specificity, sensitivity and possible cross-reactivity
between are commercially available. BRCA1/2-mutated EOCs show a higher mutational load and
a unique mutational signature with a significantly increased number of TILs, as well as elevated
PD-1 expression or PD-L1 expression in tumor-associated immune cells compared to homologous
recombination (HR)-proficient tumors.
5.1.3. Microsatellite Instability
Genomic instability, a hallmark of cancer, is generally characterized by DNA mismatch repair
(MMR) defects, which lead to MSI. Maintenance of genomic stability ensures the inheritance of
a complete copy of genetic material in the daughter cells. Moreover, during replication, cells may
develop multiple forms of mutations in several genes, such as chromosomal rearrangements, as well
as a gain or a loss of part(s) of or the entire chromosome. Repetitive sequences of 1–6 nucleotide base
pairs in DNA are known as microsatellites. In addition, alterations in microsatellites are an important
form of genomic instability, referred to as MSI. These tandem repeat sequences are dispersed across
the genomes of eukaryotes, usually in noncoding regions. Inactivation of the MMR system results in
mutations, particularly highly repetitive sequences. Additionally, the distribution of microsatellites
throughout the genome leads to MSI [45]. The reported prevalence of MSI-H status (defined by
instability in two or more markers studied) in unselected OC has ranged from 13% to 37% [46].
MMR-deficient tumors exhibit a high expression of pro-inflammatory genes, favoring the migration
and activity of CD8 + T cells [47]. Several studies suggest a better prognosis in patients with MMR
deficiency treated with immune CPIs than in MMR proficiency patients.
Even if only in a minority of EOC cases are deficient in MMR [48,49], it is worth it to note that
the Food and Drug Agency (FDA) granted anti-PD1 approval (Pembrolizumab) for MMR-deficient
cancers regardless of histology.
5.1.4. BRCA Status
BRCA status is a well-established predictor of response to PARPs, and, as already mentioned,
tumors harboring HRD have a higher predicted neo-antigen load and higher TIL infiltration [50].
However, clinical data show that response to ICI monotherapies is rare in BRCA-mutated patients
as well.
BRCA and homologous recombination deficiency (HRD) status were also evaluated in
the KEYNOTE-100 study, but no differences were observed between responders and non-responders [35].
However, in a small series of mutated BRCA patients with recurrent EOC, the use of salvage therapy
with nivolumab resulted in an ORR of 67% (4 of 6 patients) [51].
BRCA status as a response marker has also been evaluated in the TOPACIO/KEYNOTE-162
(Niraparib in combination with Pembrolizumab) and in MEDIOLA (Durvalumab in combination with
Olaparib) studies, but preliminary data did not show a correlation between the BRCA mutation and
the response to therapy [52,53].
Further data are needed to better understand the role of BRCA as a marker of response to
immunotherapy in the EOC. Moreover, consistency in terminology and thresholding is required (when
referring to HRD status) in order to optimally use such biomarkers in clinical practice, as well as
improved assays that optimize their predictive value [54].
5.1.5. Histology
Data presented from the above clinical studies were obtained from relatively small and
heterogeneous cohorts of patients. Most of them were heavily pre-treated, and different immune CPIs
Diagnostics 2020, 10, 146 7 of 17
at different dosages were used, so we are still far from understanding which is the best drug and
the best therapeutic regimen.
An interesting observation derives from the study by Hamanishi et al., which reports a complete
response in a 60 year old patient with recurrent clear-cell OC treated with nivolumab [36]. Furthermore,
Matulonis et al. [35] also reported a positive trend in the response rate of patients with clear-cell OC
treated with pembrolizumab.
These cases remain anecdotal observations; however, in clear-cell renal tumors immunotherapy
has shown a significant improvement in OS [55]. There is also evidence showing that clear-cell tumors
showed similar genetic profiles [56]; therefore, it is possible to hypothesize that this subset of patients
could benefit from immunotherapy.
More intriguing, according to the status of TIL infiltration, tumors could be histologically
categorized as “inflamed/hot tumors” or “non-inflamed/cold”. The first ones are characterized by
the presence in the tumor bed of a high density of CD8+ T cells [57,58], and such patients could benefit
from therapies acting on T cell checkpoints involved in immune tolerance. On the contrary, cold
tumors are characterized by the absence of T cells in tumor beds and are generally affected by a failure
in T cell priming, reflecting the need of strategies that could deliver autologous/allogenic effector cells
into the cancer. A third phenotype, defined as “immune-excluded”, is characterized by modification
of the tumor microenvironment (TME) and the presence of inhibitory cells that retain CD8 T cells
from entering the tumor islets, even if they are present in the stroma. Such patients could benefit
from strategies whose aim is to increase infiltrations of tumors by immune effector cells such as T cell
trafficking modulators, epigenetic modulators, TME remodeling molecules and radiation therapy [59].
5.1.6. Tumor Mutation Burden
A recent analysis in the KEYNOTE-100 showed no statistically significant differences in HRD
status among responders and non-responders and the absence of association between BRCA status and
responses. Interestingly, tumor mutation burden (TMB) and T cell-inflamed gene expression profile
(GEP) were independently predictive of response and demonstrated low correlation, suggesting that
they capture distinct features of neo-antigenicity and T cell activation.
In the recent review by Lu et al. [41], multiplex immunohistochemistry/IF and multimodality
biomarker strategies appear to be associated with improved performance over PD-L1 IHC, TMB, or
GEP alone. Further studies with composite approaches and a larger number of patients will be required
to confirm these findings to determine the most predictive combinations according to tumor type.
6. Novel Combinations
6.1. PARP Inhibitor and Immune Checkpoint Inhibitor
PARP are a family of enzymes that participate in various cellular processes adding poly
(ADP-ribose) chains onto target molecules (a process known as PARylation).
Particularly, PARP1 is mostly associated with DNA damage repair, which generates nearly
90% of poly (ADP-ribose) chains after the induction of DNA damage. This DNA repair process is
fundamental in cells that have lost homologous repair mechanisms. Indeed, PARPis are particularly
effective in cancer cells that have mutations of the genes BRCA1 or BRCA2 [60]. In fact, PARPi
interferes with homologous DNA damage repair, increases the mutational load in tumor cells and,
in mouse models with mutations in BRCA genes, activates interferon-mediated pathways by acting
in synergy with the inhibitors of immune checkpoint inhibitors [61]. Moreover, in the EOC with
BRCA1/2 mutation, higher PD-1 expression in TILs has been reported compared with homologous
recombination-proficient tumors.
Based on this rationale, the association between PARPis and immune CPIs is a potentially
successful approach for EOC therapy. Several clinical trials testing this association are currently
ongoing (Table 2).
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Table 2. Ongoing phase III trials exploring combination of CPIs and PARPIs and/or anti-VEGF drugs.
Study Setting Enrollment Arms Primary Endpoints Current Status
AGO/DUO-ENGOT
Ov46; NCT03737643
Front line and
maintenance
Stage III-IV OC, FTC, or
PPC. UPS of IDS. 1056 patients
Carboplatin-taxol + bevacizumab +
placebo followed by +bevacizumab +
placebo + placebo
Carboplatin-taxol + bevacizumab +
durvalumab (anti PD-L1) followed by
bevacizumab + durvalumab +
placebo
Carboplatin-taxol + bevacizumab +
durvalumab followed by
bevacizumab + durvalumab +
olaparib
PFS in non-tBRCA
mutated Recruiting
KEYLYNK-001/
ENGOT-ov43;
NCT03740165
Front line and
maintenance
Stage III-IV OC, FTC, or
PPC, all hystotypes
excluding mucinous,
germ cell, or borderline
tumors. UPS of IDS.
1086 patients
Carboplatin-taxol + placebo followed
by
+ placebo
Carboplatin-taxol + pembrolizumab
(anti PD-1) followed by
pembrolizumab+ placebo
Carboplatin-taxol + pembrolizumab
followed by pembrolizumab+
olaparib
PFS and OS Recruiting
GINECO/FIRST
ENGOT Ov44;
NCT03602859
Front line and
maintenance
Stage III-IV OC, FTC, or
PPC, all hystotypes
excluding mucinous,
germ cell, or borderline
tumors. UPS of IDS.
912 patients
Carboplatin taxol + placebo followed
by placebo
Carboplatin taxol + placebo +
followed by placebo+ niraparib
Carbo-tax + dostarlimab (anti
TSR042) followed by+ dostarlimab
(anti PD1) +niraparib
PFS Recruiting
ATHENA
GOG3020/ENGOT
Ov45; NCT03522246
Maintenance after
front line
Stage III-IV OC, FTC, or
PPC. Completed
first-line
platinum-based
chemotherapy and
surgery with a response.
UPS or IDS.
1012 patients
Rucaparib + nivolumab (anti PD1)
Rucaparib + placebo
Nivolumab-placebo
Placebo + placebo
PFS Recruiting
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Table 2. Cont.
Study Setting Enrollment Arms Primary Endpoints Current Status
GOG3015/ENGOT
OV39; NCT03038100 Front line
Stage III-IV OC, FTC, or
PPC with macroscopic
residual disease
postoperatively or
neoadjuvant therapy
followed by IDS.
Estimated 1300
patients
Carboplatin-taxol + bevacizumab
Carboplatin-taxol + bevacizumab +
atezolizumab (anti PD-L1)
PFS and PFS in
PD-L1 +
subpopulation;
OS and OS in PD-L1
+ subpopulation
Active
ENGOT-Ov41/GEICO
69-O/ANITA;
NCT03598270
Recurrence
Platinum sensitive
PFI > 6 months and 2
prior lines of
chemotherapy. The last
line of chemotherapy
should have included
platinum. BRCA status
known
414 patients
Carboplatin combo + niraparib
Carboplatin combo + niraparib +
atezolizumab
PFS Recruiting
ATALANTE/ENGOT
OV29; NCT02891824
Recurrence
Platinum sensitive
PFI > 6 months and 2
prior lines of
chemotherapy. The last
line of chemotherapy
should have included
platinum.
600 patients
Carboplatin combo + bevacizumab
Carboplatin combo + bevacizumab +
atezolizumab
PFS Active
EORTC-1508,
NCT02659384
Recurrence
Platinum resistant
Platinum resistant EOC,
FTC or PPC.
Any number of
platinum-based
chemotherapy lines, but
a maximum of 2
previous non-platinum
containing lines.
Prior treatment with
bevacizumab or other
targeted agents
Estimated 160
patients
Bevacizumab
Bevacizumab + atezolizumab
Bevacizumab + atezolizumab +
aspirin
PFS at 6 months Closed torecruitment
OC: ovarian cancer, FTC: fallopian tube cancer, PPC: primary peritoneal cancer, UPS: upfront primary surgery, IDS: interval debulking surgery, PFS: progression-free survival, OS:
overall survival.
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As for the first-line setting, three ongoing studies are evaluating a combination of PARPi and
CPis in front-line and as maintenance therapy after platinum-based first-line therapy (KEYLYNK-001,
FIRST, ATHENA), but no preliminary data are yet available.
In the recurrent, platinum-sensitive setting, an open-label, phase II basket study (MEDIOLA,
NCT02734004) evaluated safety and activity of Olaparib and Durvalumab association in germline
BRCA-mutated EOC patients. Preliminary results showed an 81% DCR at 12 weeks and a 63% ORR,
with good tolerability profile [62].
An ongoing phase III trial is evaluating a combination of niraparib and pembrolizumab in heavily
pretreated platinum-sensitive recurrent OC as maintenance after platinum-based chemotherapy.
In patients with platinum-resistant EOC, a phase I-II study (TOPACIO/Keynote-162, NCT02657889)
demonstrates that Niraparib combined with Pembrolizumab achieves an ORR of 25% in the overall
population with 45% in the subgroup with BRCA 1/2 mutations [63].
Moreover, an interesting phase I/II study is ongoing evaluating the combination of the anti-CTLA-4
(Tremelimumab) and Olaparib in BRCA mutated recurrent OCs (NCT0251725).
6.2. Anti-Angiogenic Drugs and Immune Checkpoint Inhibitor
Another possibility to increase the effectiveness of immune CPIs is to combine them with
angiogenesis inhibitors.
In preclinical models, a synergistic effect was observed between the alteration of tumor angiogenesis
and the increase in the immune response.
Shrimali et al. have shown that the "normalization" of the tumor vascular architecture by
inhibiting VEGF as well as improving the effectiveness of chemotherapy improves tumor infiltration
by the adoptively transferred T cells [64]. Similar results were reported by Dings et al., which showed
significant inhibition of tumor growth using adjuvant anti-angiogenic therapy in combination with
T-cell transfer [65].
Studies are currently underway to evaluate the efficacy and the safety of anti-angiogenic drugs in
combination with immune CPIs.
In particular, we have no clinical data on first-line setting, but an ongoing phase III study is
recruiting patients with newly diagnosed high-risk OC, evaluating pembrolizumab and bevacizumab
combination (GOG3015).
In patients with recurrent disease, the results of a single-arm phase 2 study on 38 patients
(18 with platinum-resistant disease and 20 with platinum-sensitive) with recurrent OC that evaluated
a combination of nivolumab and bevacizumab have been recently reported. The ORR was 40.0% in
platinum-sensitive cohort and 16.7% in platinum-resistant patients.
About 89% of patients experienced at least one treatment AEs of any grade, while 23.7% experienced
≥3 AEs. The results of this study suggest an activity of this combination in platinum-sensitive EOC [66].
As for platinum-resistant patients, a phase 1 study tested durvalumab plus cediranib in 14 patients
with a 55% ORR; however, frequent severe AEs were reported for this association (hypertension and
diarrhea) [67].
In this setting an interesting three-arm phase III study recruited platinum-resistant ROC
randomized patients to bevacizumab alone or in combination with atezolizumab or in triplet with
atezolizumab and aspirin. The primary endpoint is 6 months PFS. Recruitment is closed and results
are awaited.
6.3. Triplets Including PARPi, Anti-Angiogenic Drugs and an Immune Checkpoint Inhibitor
A powerful strategy may combine CPIs with both PARPis and immune-checkpoint inhibitors.
Clinical data will be provided by DUO Phase III study that recruits Stage III-IV OC. Patients will receive
platinum-based therapy with bevacizumab and durvalumab followed by maintenance bevacizumab,
durvalumab plus olaparib or placebo in arms A and B respectively.
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A complete list of ongoing phase III trials exploring ICIs and PARPIs and/or anti-VEGF
combinations are listed in Table 2, while the preliminary results of drug combinations are reported in
Table 3.
6.4. Radiotherapy and Immune Checkpoint Inhibitor
There is a potential rationale for the use of radiotherapy plus immune CPIs in patients with
advanced EOC. Low doses of radiation therapy can induce DNA damage and trigger an “in situ
vaccination” process by activating antigen-presenting cells and enhancing the cell-mediated immune
response. Moreover, radiotherapy can trigger the apoptosis of Treg lymphocytes, further promoting
the activity of cytotoxic T-cells [68].
In this context, radiotherapy can enhance the immune response against EOC and the effects
of immunotherapy. Recently, some authors have demonstrated a role of radiotherapy alone in
oligometastatic EOC [68–70], and some clinical studies are evaluating the efficacy and safety of
checkpoints combined with radiotherapy. The most effective radiotherapy dosage and fractionation to
obtain the activation of the immune response are still to be defined. In addition, pelvic and abdominal
radiotherapy may have important gastrointestinal and urinary toxicities [68,71,72].
6.5. Chemotherapy and Immune Checkpoint Inhibitor
Strong preclinical data suggest that chemotherapy could improve the activity of CPIs. Indeed,
adding carboplatin to PD-L1 antibodies increases CD4 and CD8 T lymphocytes reducing T reg cells,
while the addition of paclitaxel to a PD-L1/PD-1 inhibitor increases PD-L1 expression and survival of
mice [73].
Based on these premises, two phase III trials evaluated the combination of avelumab to standard
chemotherapy in frontline treatment (JAVELIN 100) and in platinum-resistant disease (JAVELIN 200).
JAVELIN 100 is a phase III randomized trial that evaluated avelumab both in combination or
only as maintenance therapy after carboplatin and paclitaxel in first line. The study was prematurely
terminated on the basis of the results of a planned interim analysis that showed futility of efficacy in
Dec 2019 (NCT02718417).
JAVELIN 200 recruited 566 patients with platinum-resistant disease and no more than 3 prior
therapies, randomizing them to pegylated liposomal doxorubicin (PLD), avelumab or both of them.
Primary end points were PFS and OS. Combination of PLD and avelumab did not prolong the median
PFS (3.5 months vs 3.7 months) or the median OS (13.1 months vs 15.7 months) (hazard ratio, 0.89; 95%
CI, 0.74–1.24) [74].
These results suggest that a combination of chemotherapy and CPIs might not be the most
successful strategy for OC patients. The role of chemotherapy with immunotherapy needs further
investigation, but it could play a role in combination with adoptive therapies (that are based on
the infusion of autologous or allogenic immune cells that actively kill cancer cells) [75].
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Table 3. Results in trials exploring combination therapy (ICIs + PARPi or anti-VEGF).
Study Patient Selection Number ofPatients Treatment
Most Common
Adverse Events
Reported any Grade
DCR ORR
MEDIOLA,
NCT02734004
Recurrent platinum-sensitive
OC, FTC, PPC with germline
BRCA mutations in
second-line or later therapy
32
Durvalumab (anti
PD-1) + olaparib
Durvalumab +
olaparib +
bevacizumab
Hypothyroidism
(15%); cutaneous rash
(12%)
81% at 12 weeks 63% at 12 weeks
TOPACIO/Keynote-162,
NCT02657889
Recurrent OC, FTC, PPC with
germline BRCA mutations 60
Pembrolizumb (anti
PD-1) + niraparib
Fatigue (53%), nausea
(42%), anemia (36%),
constipation (36%)
45% 25%
NCT02484404
Recurrent OC, FTC, PPC
received least two prior
platinum-containing
regimens, platinum resistant
or refractory
26
Durvalumab +
olaparib (N = 12) or
cediranib (n = 14)
Olaparib arm:
fatigue (75%), nausea
(58%), Abdominal
pain (42%) (any
grade); Cediranib
arm: hypertension
(86%), diarrhea (72%)
(any grade)
Not reported 17% (Olaparib arm);55% (Cediranib arm)
NCT02873962
Recurrent OC, FTC, PPC. All
histotypes.
Platinum-resistant or
platinum-sensitive disease.
38 Nivolumab (antiPD-1) + bevacizumab
Fatigue (47%),
headache (29 %),
myalgia (29%), serum
amylase level increase
(29%) (any grade).
Not reported
40.0% in
platinum-sensitive
(patients) 16.7% in
platinum-resistant
(patients)
ICIs: immune checkpoint inhibitors, PARPi: inhibitors of poly (ADP-ribose) polymerase, VEGF: vascular endothelial growth factor, OC: ovarian cancer, FTC: fallopian tube cancer, PPC:
primary peritoneal cancer, DCR: disease control rate, ORR: objective response rate.
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7. Conclusions
Immunotherapy has dramatically changed the prognosis of several cancers such as NSCLC
melanoma, bladder and kidney cancer. Although CPIs use in EOC is strongly sustained by preclinical
rationale, clinical results from early development trials are largely disappointing so far.
A better selection of patients based on tumor histology, BRCA/HRD status, and previous treatments
may improve these results.
The main objective is to personalize immunotherapy in order to efficiently cure EOC patients,
avoid unnecessary toxicities and reduce the costs for the healthcare systems [76]. Improvement of
academic studies and translational research is crucial to improve survival of EOC patients.
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